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Aims Aim of this study was to evaluate a possible association between endocannabinoid (EC) plasma levels, such as ana-
ndamide (AEA) and 2-arachidonoylglycerol (2-AG), and coronary circulatory function in obesity.
Methods
and results
Myocardial blood flow (MBF) responses to cold pressor test (CPT) and during pharmacological vasodilation with
dipyridamole were measured with 13N-ammonia PET/CT. Study participants (n ¼ 77) were divided into three
groups based on their body mass index (BMI, kg/m2): control group 20≤ BMI ,25 (n ¼ 21); overweight group,
25≤ BMI ,30 (n ¼ 26); and obese group, BMI ≥30 (n ¼ 30). Anandamide plasma levels, but not 2-AG plasma
levels, were significantly elevated in obesity as compared with controls, respectively [0.68 (0.53, 0.78) vs. 0.56
(0.47, 0.66) ng/mL, P ¼ 0.020, and 2.2 (1.21, 4.59) vs. 2.0 (0.80, 5.90) ng/mL, P ¼ 0.806)]. The endothelium-related
change in MBF during CPT from rest (DMBF) progressively declined in overweight and obese when compared
with control group [0.21 (0.10, 0.27) and 0.09 (20.01, 0.15) vs. 0.26 (0.23, 0.39) mL/g/min; P ¼ 0.010 and
P ¼ 0.0001, respectively). Compared with controls, hyperaemic MBFs were significantly lower in overweight and
obese individuals [2.39 (1.97, 2.62) vs. 1.98 (1.69, 2.26) and 2.10 (1.76, 2.36); P ¼ 0.007 and P ¼ 0.042, respectively)].
In obese individuals, AEA and 2-AG plasma levels were inversely correlated with DMBF to CPT (r ¼ 20.37,
P ¼ 0.046 and r ¼ 20.48, P ¼ 0.008) and hyperaemic MBFs (r ¼ 20.38, P ¼ 0.052 and r ¼ 20.45, P ¼ 0.017),
respectively.
Conclusions Increased EC plasma levels of AEA and 2-AG are associated with coronary circulatory dysfunction in obese individ-
uals. This observation might suggest increases in EC plasma levels as a novel endogenous cardiovascular risk factor in
obesity, but needing further investigations.
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Introduction
Over the last decades there has been a steady increase in the
prevalence of obesity in industrialized nations as high as
30%.1,2 Since obesity has been recognized as a risk factor of
cardiovascular morbidity and mortality, the increasing prevalence
of obesity emerges as a considerable public health problem.2
The mechanisms by which obesity may initiate and accelerate cor-
onary vascular disease remain largely unknown. Previous studies
have shown an association between obesity and endothelial
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dysfunction as a functional precursor of the coronary artery
disease (CAD) process.3–5 In particular, the previously reported
independent predictive value of obesity for coronary circulatory
dysfunction3,4 suggests direct mediators released from the
adipose tissue, so-called adipocytokines, such as leptin, adiponec-
tin, and/or local mediators such as the endocannabinoids (ECs)
to be involved in the regulation of coronary vasomotor tone and
thus in the initiation and development of CAD.6–8 Endocannabi-
noids (EC), such as anandamide (AEA) and 2-arachidonoylglycerol
(2-AG), are endogenous bioactive lipid mediators deriving from
arachidonic acid, which are physiologically synthesized and released
upon demand from the brain, peripheral organs, and adipose
tissue and exert their biological effects via interaction with specific
G-protein-coupled cannabinoid receptors type 1 (CB1) and type 2
(CB2).6 In the experimental setting, increases in adipose-derived
ECs have been suggested to exert proatherosclerotic effects by
signalling via CB1 and/or non-CB receptors in the vascular wall
with resultant increases in oxidative stress, vascular smooth
muscle cell proliferation, and recruitment of monocytes and neu-
trophils into the arterial wall.6,9 This may contrast with recent
findings in ApoE2/2 mice, in whom the stimulation of CB2 recep-
tor appeared to mediate anti-inflammatory and anti-
atherosclerotic effects.6,10 More recently, elevated plasma levels
of the EC 2-AG, but not AEA, were found to be associated with
atherosclerotic disease in a hypercholesterolaemic mouse
model.9 In light of this, it is intriguing to hypothesize that an abnor-
mal function of the coronary circulation as a result of increases in
EC plasma levels may provide a mechanistic link between obesity
and the initiation and progression of cardiovascular disease.
To this end, we aimed to evaluate in normal, overweight, and
obese individuals, without traditional cardiovascular risk factors, a
possible association between EC plasma levels, such as AEA and
2-AG, and coronary circulatory function.
Methods
Study population and design
The study population comprised 77 individuals (41 men and 36
women; mean age 43.3+11.2 years) with no arterial hypertension
(blood pressure ,140/90 mmHg), smoking, and diabetes mellitus
(fasting plasma glucose obtained on more than two occasions
≤126 mg/dL) (Table 1). Study participants underwent an initial screen-
ing visit that comprised a physical examination, electrocardiogram
(ECG), blood pressure measurements, and routine blood chemistry
in a fasting state. Any study applicants with any cardiac or vasoactive
medication, a history of variant angina, a family history of premature
CAD, or clinically manifest cardiovascular or any other disease were
excluded from the study. Physical examination revealed normal find-
ings in all study participants and they had normal resting ECGs.
Study participants then underwent 13N-ammonia PET/CT (64-slice
Biograph HiRez TruePoint PET-CT scanner, Siemens, Erlangen,
Germany) measurements of myocardial blood flow (MBF) at rest
and during vasomotor stress in the morning in a fasting state to
evaluate coronary circulatory function. A prerequisite for the study
inclusion was a normal stress-rest perfusion imaging on
13N-ammonia PET/CT, which widely excluded the presence of flow-
limiting CAD lesions.3 Recruited study participants were subsequently
grouped according to their body mass index (BMI, kg/m2): control
group, 20≤ BMI ,25 (CON; n ¼ 21); overweight group, 25≤ BMI
,30 (OW; n ¼ 26); obese group, ≥30 (OB; n ¼ 30).
Blood chemistry included plasma glucose, haemoglobin A1c, insulin,
total cholesterol, HDL and LDL cholesterol, triglycerides levels, and
high-sensitive C-reactive protein. Assessment of insulin resistance
using the Homeostasis Model Assessment (HOMA) was determined
as described previously.3 In each study participant, EC plasma levels
were determined from peripheral arm vein blood samples. Endocanna-
binoids, AEA, and 2-AG were extracted from 100 mL of human plasma
by liquid–liquid extraction and separated by liquid chromatography
(Ultimate 3000 RS, Dionex, CA, USA). Analyses were performed on
a 5500 QTrapw triple quadrupole/linear ion trap (QqQLIT) mass
spectrometer equipped with a TurboIon-SprayTM interface (AB
Sciex, Concord, ON, Canada).11 The study was approved by the Uni-
versity Hospitals of Geneva Institutional Review Board (No: 07-183),
and each participant signed the approved informed consent form.
Assessment of myocardial flow with PET/CT
Following the topogram used to define the axial field-of-view and a
low-dose CT scan (120 kV, 30 mA) for attenuation correction, PET
emission data were acquired during shallow breathing following intra-
venous injection of 13N-ammonia. At first, PET scanning in fully 3D
mode at rest started immediately following injection of 500–
550 MBq of 13N-ammonia for a total duration of 18 min in list-mode
format and 21 dynamic frames of the ungated first 6 min data (12 ×
10, 3 × 20, 6 × 30 s) were reconstructed using iterative normalized
attenuation-weighted ordered subsets expectation maximization
(NAW-OSEM). The CT-based attenuation correction map was
used to reconstruct the PET emission data. The default parameters
used were ordered OSEM with eight iterations and four to six
subsets followed by a post-processing Gaussian filter. Time-activity
curves from the first 12-dynamic frames (12 for 10 s each), in
concert with a two-compartment tracer kinetic model,12 were
used to calculate MBF in mL/g/min of the left ventricle with the
use of the PMOD software package (version 2.8 PMOD Technol-
ogies Ltd, Zurich, Switzerland).13 The tracer kinetic model applied,
corrected for physical decay of 13N-ammonia, partial- volume-related
underestimations of true myocardial tissue concentrations (by assum-
ing a uniform myocardial wall thickness of 1 cm). Further, correction
for scatter and random counts, and spillover of radioactivity between
the left ventricular blood pool and myocardium was performed
according to Hutchins et al.14 Following, 12 min ECG-gated PET
emission data were acquired with 10 frames per cardiac cycle. The
gated PET emission data were used for the analysis of the relative
13N-ammonia uptake of the left-ventricle and, thus, myocardial per-
fusion was evaluated visually on reoriented short- and long-axis myo-
cardial slices and semiquantitatively on the corresponding polar map
from the last static 18 min transaxial PET image. Second, sympathetic
stimulation with cold pressor test (CPT) was performed with the
study participant immersing one hand in a slush of ice water. At
60 s, 500–550 MBq 13N-ammonia was administered and serial
PET images were acquired while immersion of the hand in ice
water continued for at least another 60 s. The initially acquired
low-dose CT scan was applied for attenuation correction of the
PET emission data. The CPT-induced and predominantly
endothelium-related flow alteration from rest was defined as the
difference between rest and CPT-related MBF (DMBF). This
endothelium-related flow parameter was chosen as it had been
described to be widely independent of age, gender, haemodynamic
conditions, and resting MBF.15 Third, hyperaemic MBF was induced
with the intravenous standard dose of 140 mg/kg/min with dipyrida-
mole over 4 min. After an additional 3 min at the peak effect of
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pharmacological vasodilation of the arteriolar vessels, 500–
550 MBq 13N-ammonia was injected intravenously again and acqui-
sition of PET emission data was started. The stress PET scan was fol-
lowed by a low-dose CT scan for attenuation correction of the PET
stress images during pharmacological vasodilation. This was deemed
necessary to account for possible changes in cardiac and pulmonary
volumes owing to dipyridamole-induced hyperaemia. Finally, the
physical half-life (9.8 min) of 13N-ammonia necessitated a time inter-
val of 45 min between repeat assessments of MBF with PET.7
A heart rate, blood pressure, and a 12-lead ECG were recorded
continuously during each MBF measurement. From an average of
heart rate and systolic blood pressure (SBP) during the first 2 min of
each image acquisition, the rate–pressure product (RPP) was
derived as an index of cardiac work. To account for possible interindi-
vidual variations in coronary driving pressure, an index of global coron-
ary vascular resistance (CVR) was determined as the ratio of mean
arterial blood pressure (mmHg) to MBF (mL/g/min). In addition, MBF
was normalized to the RPP, and thus myocardial work (averaged
during the first 2 min of image acquisition; MBF divided by RPP multi-
plied by 10 000). Finally, the short- and long-term reproducibility of
MBF responses to CPT and pharmacological vasodilation have been
reported previously.7,16
Statistical analysis
Since continuous variables are not always normally distributed,
they are presented as median and inter-quartile range (25th to
75th percentile: Q1, Q3). For comparison of differences, Mann–
Whitney U test for independent samples was used (Statistical
Analysis Software Institute, Cary, NC, USA). A comparison of
CPT-induced change in MBF and dipyridamole MBFs between
the different groups was performed by one-way analysis of
variance (ANOVA), followed by Scheffe’s multiple comparison
test. Pearson’s correlation coefficient (r), assuming a linear
regression, and the standard error of the estimate (SEE) was cal-
culated to investigate the associations between CPT- and
dipyridamole-induced changes in MBFs and laboratory parameters.
Multivariate analysis was performed by means of a linear step-wise
regression model adjusting for the following a priori selected pre-
dictors of the CPT-induced DMBF and hyperaemic MBF during
dipyridamole stimulation: age, BMI, gender, AEA, 2-AG, SBP,
total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides,
glucose, HOMA, and C-reactive protein. All test procedures were
two-tailed, and P ≤ 0.05 was considered statistically significant.
Based on a standard deviation of 0.18 and 0.17 of DMBF to
CPT and hyperaemic MBF,17 respectively, and a minimum clinically
relevant difference in DMBF of 0.20 mL/g/min and in hyperaemic
MBF of 0.22 mL/g/min, a ¼ 0.05, and a power (1 2 b) of 0.8,
the number of patients necessary for the cross-sectional baseline
analysis was calculated to be 25 and 23, respectively.
Results
Patient characteristics and metabolic
profile
The clinical characteristics and laboratory measurements among
the groups studied are shown in Table 1. The increase in BMI
among study participants was paralleled by the waist–hip ratio
(WHR). The BMI significantly correlated with the WHR (r ¼
0.62, SEE ¼12.32, P, 0.0001). Endocannabinoid plasma levels
did not differ significantly between CON and OW. Conversely,
AEA plasma levels were significantly higher in OB than in CON
and OW, while this was not observed for 2-AG (Table 1).
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Table 1 Characteristics of study population (n 5 77)
CON (n 5 21) OW (n5 26) P-value OB (n5 30) P-value
BMI, kg/m2 21.1 (20.5, 22.6) 26.93 (25.91–28.22) 0.0001 41.3 (31.75–45.45) 0.0001
Waist–hip ratio 0.84 (0.80, 0.88) 0.89 (0.84–0.93) 0.023 0.96 (0.91–0.98) 0.0001
Age, years 40.0 (33.5, 46.5) 44.0 (33.0, 51.5) 0.304 44.0 (35.5, 56.5) 0.162
Gender, F/M 10/11 12/14 0.146 14/16 0.354
AEA, ng/mL 0.56 (0.47, 0.66) 0.52 (0.41, 0.67) 0.630 0.68 (0.53, 0.78) 0.020
2-AG, ng/mL 2.0 (0.80, 5.90) 1.4 (0.72, 2.08) 0.181 2.2 (1.21, 4.59) 0.806
Lipid status
Cholesterol levels, mg/dL 191.1 (165.8, 2228.2) 202.8 (170.6, 224.2) 0.563 191.1 (158.0–212.6) 0.871
LDL level, mg/dL 121.7 (105.5, 145.1) 128.5 (113.0, 146.1) 0.531 118.6 (102.3, 141.4) 0.934
HDL level, mg/dL 54.6 (39.4, 64.0) 45.0 (37.7, 54.2) 0.033 42.1 (37.2, 47.8) 0.006
Triglyceride level, mg/dL 54.3 (50.3, 89.9) 93.0 (60.1, 117.0) 0.016 117.5 (77.9–126.4) 0.0001
Glucose level, mg/dL 91.9 (81.9, 99.9) 97.3 (87.8, 102.7) 0.090 100.9 (92.3, 106.0) 0.007
Insulin, mUI/L 3.1 (1.9, 5.2) 5.4 (3.4, 10.9) 0.016 9.4 (7.3, 19.4) 0.0001
HOMA 0.72 (0.44, 1.33) 1.44 (0.71, 2.61) 0.023 2.25 (1.79, 4.29) 0.0001
C-reactive protein levels, mg/L 0.9 (0.9, 3.0) 1.0 (0.9, 2.8) 0.616 5.0 (1.4, 7.5) 0.0001
HbAlc, % 5.2 (4.9, 5.4) 5.2 (5.0, 5.3) 0.745 5.3 (5.1, 5.8) 0.289
Values are median (Q1, Q3). CON, controls; OW, overweight; OB, obesity; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; BMI, body mass index; HbAlc, haemoglobin Alc;
HDL, high-density lipoprotein; HOMA, Homeostasis Model Assessment; LDL, low-density lipoprotein.
P-values vs. CON (Mann–Whitney U test for independent samples).
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Correlations between metabolic
parameters
With respect to the entire study population, Pearson’s regression
analysis denoted significant correlations between BMI and insulin
resistance (HOMA) (r ¼ 0.58, SEE ¼0.45; P ¼ 0.0001), BMI and
AEA (r ¼ 0.46, SEE ¼5.12; P ¼ 0.0001), and a non-significantly
for the relation between BMI and 2-AG (r ¼ 0.20, SEE ¼0.22;
P ¼ 0.088). In addition, HOMA correlated with AEA (r ¼ 0.36,
SEE ¼1.59; P ¼ 0.006), and 2-AG (r ¼ 0.30, SEE ¼0.063; P ¼
0.028), respectively. These observations may denote a close
interrelation between these metabolic parameters. As regards
the HDL cholesterol, it also showed significant and inverse cor-
relations with BMI (r ¼ 20.34, SEE ¼0.079 P ¼ 0.004), and
HOMA (r ¼ 20.29, SEE ¼0.76; P ¼ 0.035), but not with AEA
(r ¼ 0.08, SEE ¼8.37; P ¼ 0.510) or 2-AG (r ¼ 20.14, SEE
¼0.32; P ¼ 0.239), respectively. Furthermore, the regression
analysis demonstrated significant correlations between BMI and
C-reactive protein plasma levels (r ¼ 0.57, SEE ¼0.19; P ¼
0.0001), HOMA, and C-reactive protein (r ¼ 0.32, SEE ¼0.26;
P ¼ 0.017), AEA and C-reactive protein (r ¼ 0.25, SEE ¼2.87;
P ¼ 0.034), but none between 2-AG and C-reactive protein
(r ¼ 0.12, SEE ¼0.115; P ¼ 0.312). These findings may suggest
some association between metabolic and inflammatory cardiovas-
cular disease mechanisms.
Haemodynamic parameters
At baseline, the heart rate and SBP were comparable between
CON and OW, while they were higher in OB (Table 2). As a
consequence, the resting RPP was significantly higher in OB
than in OW (P ¼ 0.005) and CON, while it did not differ
between OW and CON (P ¼ 0.716). Sympathetic stimulation
with CPT induced a significant increase in the heart rate and
SBP in each group, so that the RPP was significantly higher
during CPT than at baseline. The increase in the RPP (DRPP)
as a result of the CPT-induced sympathetic stimulation was
not significantly different between CON, OW, and OB
(Table 2), indicating comparable increases in myocardial work-
load among the groups studied. As regards the pharmacologi-
cally induced hyperaemia with dipyridamole, there was a
significant increase in the heart rate in the three study groups,
while blood pressures mildly decreased. The change in RPP
(DRPP) during dipyridamole-stimulation remained similar among
these groups (Table 2).
Myocardial blood flow
At baseline, MBF was comparable between CON and OW but
significantly higher in OB (Table 3). When adjusted for RPP, the
normalized myocardial blood flow (NMBF) at rest was compar-
able among groups (Table 3). Conversely, the MBF and NMBF
during CPT progressively decreased from CON to OW and
OB. As regards the endothelium-related change of MBF during
CPT from rest (DMBF to CPT), it was significantly less in
OW and OB than in CON, respectively (Table 3, Figure 1A).
In addition, DMBF to CPT was significantly more diminished in
OB than in OW (Table 3, Figure 1A). The group comparison
between the DMBF to CPT in CON was significant when com-
pared with OW and OB (P ¼ 0.0001 by ANOVA). As changes
of CVR mirrored those of MBF for each study group
(Table 3), differences in haemodynamic responses can be
widely ruled out as possible cause for the observed alteration
in MBF response to CPT.
As regards the MBFs during dipyridamole-induced pharmaco-
logical vasodilation, they were significantly lower in OW and
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Table 2 Haemodynamic findings PET/CT exam
Group
CON OW P-value OB P-value
Haemodynamics at rest
Heart rate (b.p.m.) 62.0 (58.0, 69.5) 62.5 (54.8, 69.3) 1.000 67.0 (63.0, 75.0) 0.015
Systolic blood pressure (mmHg) 115 (109.5, 126.0) 119.0 (112.8, 126.5) 0.341 124.0 (111.5, 134.0) 0.047
RPP 6831.0 (6420.5, 7815.0) 7239.5 (6474.8, 7841.5) 0.716 8580.0 (7155.0, 9619.5) 0.003
CPT
Heart rate (b.p.m.) 74.0 (62.5, 85.0) 70.5 (60.0, 78.0) 0.239 75.0 (66.0, 82.0) 0.637
Systolic blood pressure (mmHg) 135 (127.0, 144.0) 135.5 (126.8, 148.5) 0.615 151.0 (139.5, 158.5) 0.002
RPP 9240.0 (8649.0, 11002.0) 9637.5 (8290.0, 10572.0) 0.781 11376.0 (9379.5, 12528.0) 0.031
DRPP (CPT-rest) 2469.0 (1834.0, 3036.0) 1861.5 (999.5, 3032.8) 0.185 2648.0 (1013.0, 3839.0) 0.914
Pharmacological vasodilation
Heart rate (b.p.m.) 85.0 (73.0, 92.5) 85.0 (79.3, 91.8) 0.983 87.0 (82.0, 101.0) 0.137
Systolic blood pressure (mmHg) 114 (106.0, 118.5) 118 (111.0, 122.5) 0.139 120.0 (115.0, 133.0) 0.002
RPP 9118.0 (8258.5, 10451.0) 9895.5 (8977.2, 11001.25) 0.280 11310.0 (10353.0, 12272.0) 0.0001
DRPP (pharmacological-rest) 2044.0 (1133.5, 3023.5) 2221.0 (1532.5, 3827.1) 0.460 2533.0 (1725.0, 3984.0) 0.201
Values are median (Q1, Q3). CON, controls; OW, overweight; OB, obesity; RPP, rate-pressure product; CPT, cold pressor test.
P-values vs. CON (Mann–Whitney U test for independent samples).
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OB compared with CON, respectively, while they remained
comparable between OW and OB (Table 3, Figure 1B). Similarly,
the MFR progressively declined from CON to OW and OB,
while it did not differ between OW and OB (P ¼ 0.270)
(Table 3). The group comparison of dipyridamole-stimulated
MBFs and MFR in CON was significantly different from those
in the OW and OB (P ¼ 0.010 by ANOVA). Further, the
CVR during dipyridamole stimulation was significantly higher in
OW and OB than in CON, confirming the reduced vasodilatory
capacity in individuals with increased body weight (Table 3).
Changes in myocardial blood flow related
to endocannabinoid plasma levels
With regard to the entire study population, Pearson regression
analysis demonstrated significant and inverse correlations
between AEA and 2-AG plasma levels and endothelium-related
DMBF to CPT, respectively (r ¼ 20.37, SEE ¼0.18; P ¼ 0.001
and r ¼ 20.22, SEE ¼0.18; P ¼ 0.052), as well as for
dipyridamole-induced hyperaemic MBFs, respectively
(r ¼ 20.23, SEE ¼0.45; P ¼ 0.052 and r ¼ 20.30, SEE ¼0.44;
P ¼ 0.010) (Table 4). In OW, AEA, and 2-AG plasma levels
were not correlated with DMBF to CPT (r ¼ 20.19, SEE
¼0.17; P ¼ 0.337 and r ¼ 20.17, SEE ¼0.17; P ¼ 0.401) and
hyperaemic MBFs (r ¼ 20.11, SEE ¼0.44; P ¼ 0.604 and
r ¼ 20.28, SEE ¼0.43; P ¼ 0.174), respectively. Conversely, in
OB there were significant associations between AEA and
2-AG plasma levels and endothelium-related DMBF to CPT,
respectively (Figure 2), and for dipyridamole-induced hyperaemic
MBFs, respectively (Figure 3). These correlations were also main-
tained when corresponding CVR values of the CPT- and
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Table 3 Myocardial blood flow findings during PET/CT exam
MBF (mL/min/g) Group
CON OW P-value OB P-value
MBF at rest 0.69 (0.63, 0.79); 0.71+0.10 0.70 (0.61, 0.76); 0.70+0.11 0.756 0.81 (0.64, 0.95); 0.81+0.18 0.040
NMBF at rest 0.92 (0.85, 1.13); 0.99+0.17 0.95 (0.83, 1.09); 0.98+0.18 0.608 0.95 (0.84, 1.15); 0.97+0.21 0.776
MBF during CPT 1.0 (0.86, 1.21); 1.04+0.21 0.88 (0.80, 1.04); 0.91+0.19 0.040 0.91 (0.74, 0.96); 0.88+0.18 0.008
△MBF to CPT from rest 0.26 (0.23, 0.39); 0.34+0.17 0.21 (0.10, 0.27); 0.21+0.17 0.010 0.09 (20.01, 0.15); 0.07+0.12 0.0001
NMBF during CPT 1.05 (0.92, 1.15); 1.06+0.18 0.93 (0.85, 1.09); 0.96+0.18 0.087 0.763 (0.67, 0.93); 0.81+0.17 0.0001
MBF during
pharmacological
vasodilation
2.39 (1.97, 2.62); 2.37+0.49 1.98 (1.69, 2.26); 1.96+0.43 0.007 2.10 (1.76, 2.36); 2.05+0.40 0.042
MFR 3.4 (2.95, 3.85); 3.38+0.67 2.92 (2.36, 3.28); 2.88+0.75 0.012 2.70 (2.27, 3.15); 2.63+0.76 0.001
CVR (mmHg/mL/min/g)
At rest 119.0 (103.4, 133.6) 130.9 (116.8, 142.0) 0.091 111.9 (95.2, 136.0) 0.356
During CPT 96.1 (73.4, 110.9) 114.6 (97.3, 134.4) 0.003 128.2 (111.9, 140.7) 0.0001
△ change to CPT from
rest
225.3 (236.9, 215.7) 211.6 (231.3, 20.6) 0.023 10.3 (22.8, 18.3) 0.0001
Pharmacological
vasodilation
33.6 (29.0, 37.9) 43.3 (36.2, 49.6) 0.001 42.7 (36.9, 49.5) 0.002
Values are median (Q1, Q3) and mean+ SD. CON, controls; OW, overweight; OB, obesity; MBF, myocardial blood flow; NMBF, normalized MBF; MFR, myocardial flow reserve;
CVR, coronary vascular resistance.
P-values vs. CON (Mann–Whitney U test for independent samples).
Figure 1 (A) Change in endothelium-related myocardial blood
flow from rest in response to cold pressor testing, and (B) hyper-
aemic MBFs during pharmacological vasodilation with dipyrida-
mole in controls (CON), overweight (OW), and obesity (OB).
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dipyridamole-induced flow response were evaluated, respectively
(DCVR to CPT and AEA: r ¼ 0.41, SEE ¼17.7; P ¼ 0.028 and
with 2-AG: r ¼ 0.38, SEE ¼0.60; P ¼ 0.039; and between hyper-
aemic CVR and AEA: r ¼ 0.47, SEE ¼11.6; P ¼ 0.013, and with
2-AG: r ¼ 0.63, SEE ¼0.34; P ¼ 0.0001).
Determinants of change in myocardial
blood flow to cold pressor test
Considering the entire study group, on univariate analysis age, BMI,
gender, AEA and 2-AG plasma levels, SBP, HDL cholesterol, trigly-
cerides, glucose, and C-reactive protein levels were significantly
associated with endothelium-related DMBF to CPT (Table 4). As
denoted in Table 4, by multivariate analysis only BMI and gender
correlated in an independent fashion with DMBF. The univariate
analysis in OW (Table 5) identified only gender to be significantly
associated with DMBF. Conversely, in OB (Table 5), gender,
SBP, AEA, and 2-AG plasma levels were significantly associated
with DMBF.
Determinants of hyperaemic myocardial
blood flows
As regards the dipyridamole-stimulated hyperaemic MBFs in the
entire study group, on univariate analysis they correlated with
age, AEA and 2-AG plasma levels, and HDL cholesterol
(Table 4). By multivariate analysis, only 2-AG plasma levels
remained independently associated with hyperaemic MBFs. On
the univariate analysis in OW (Table 5) no association with hyper-
aemic MBFs was identified. Conversely, as denoted in Table 5, age,
gender, and AEA and 2-AG plasma levels were significantly associ-
ated with hyperaemic MBFs in OB.
Discussion
The present study is unique in that it identifies increases in EC
plasma levels to be significantly associated with an impairment of
coronary circulatory function in OB. Increases in EC plasma
levels, such as of AEA and 2-AG, were associated with an abnormal
functioning of the coronary endothelium and arteriolar vascular
smooth muscle cells in obese individuals. As an impairment of
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Table 4 Entire study group
DMBF to CPT Hyperaemic MBF
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Coefficient
b (95% CI)
P-value Coefficient
b (95% CI)
P-value Coefficient
b (95% CI)
P-value Coefficient
b (95% CI)
P-value
Age, years 20.23 (20.008
to 0.0001)
0.043 — — 20.27 (20.021
to 20.002)
0.017 — —
BMI, kg/m2 20.54 (20.016
to 20.008)
0.0001 20.56 (20.017
to 20.007)
0.0001 20.16 (20.020
to 0.004)
0.177 — —
Gender, M 20.33 (20.22
to 20.044)
0.003 20.36 (20.23
to 20.050)
0.002 20.23 (20.43
to 0.0001)
0.216 — —
AEA, ng/mL 20.36 (20.618
to 20.159)
0.001 — — 20.227 (21.183
to 0.006)
0.052 — —
2-AG, ng/mL 20.22 (20.019
to 0.0001)
0.052 — — 20.297 (20.058
to 20.002)
0.010 20.297 (20.058
to 20.002)
0.034
SBP, mmHg 20.27 (20.008
to 0.0001)
0.016 — — 20.17 (20.016
to 0.003)
0.157 — —
Total cholesterol, mg/dL 20.024 (20.002
to 0.001)
0.841 — — 0.047 (20.003
to 0.004)
0.697 — —
LDL cholesterol, mg/dL 20.11 (20.002
to 0.001)
0.336 — — 20.027 (20.004
to 0.003)
0.824 — —
HDL cholesterol, mg/dL 0.38 (0.002
to 0.009)
0.001 — — 0.27 (0.001
to 0.018)
0.023 — —
Triglycerides, mg/dL 20.28 (20.002
to 0.0001)
0.016 — — 20.070 (20.002
to 0.001)
0.557 — –
Glucose, mg/dL 20.22 (20.005
to 0.0001)
0.054 — — 20.18 (20.010
to 0.001)
0.121 — —
HOMA 20.22 (20.042
to 0.004)
0.108 — — 20.18 (20.096
to 0.020)
0.196 — —
C-reactive protein, mg/L 20.23 (20.019
to 0.0001)
0.049 — — 0.048 (20.020
to 0.030)
0.688 — —
MBF, myocardial blood flow; CPT, cold pressor testing; BMI, body mass index; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; SBP, systolic blood pressure; LDL cholesterol,
low-density lipoprotein cholesterol; HDL cholesterol, high-density lipoprotein cholesterol; HOMA, homeostasis model assessment for insulin resistance. P-values by analysis of
variance.
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coronary circulatory function has been widely appreciated as a
functional precursor of the CAD process and future cardiovascular
events,7,13 the observed direct and close associations between
increases in EC plasma levels and coronary circulatory dysfunction
may suggest increases in EC plasma levels such as of AEA and
2-AG as a potential novel risk factor for the initiation and develop-
ment of CAD in OB, which, however, warrants further
investigations.
Metabolic profiles and interrelations
As observed in the current and in a recent investigation,18 the
median value of AEA plasma levels were significantly increased
in OB when compared with CON, while this was not observed
for 2-AG. In the OW again, AEA and 2-AG plasma levels did not
differ significantly from those in CON. Differences in the charac-
teristics of the present cohort of participants, and in particular
the prevalence of women vs. men, might also explain why the
plasma levels of AEA but not those of 2-AG were found here
to be significantly increased in OB. In fact, previous studies
have demonstrated that elevated plasma levels of 2-AG are
most often found in men with abdominal OB, whereas elevated
plasma levels of AEA are observed in post-menopausal
women.19,20 These divergent characteristics of AEA and 2-AG
concentrations in individuals with increasing body weight remain
to be further elucidated but they may be related to different
(patho-)physiological roles of these compounds. For example,
AEA also stimulates non-CB receptors such as transient receptor
potential vanilloid type-1 channels, and, with increasing concen-
trations, PPAR-g.6 Conversely, 2-AG has been described to act
more selectively on CB receptors. It is also conceivable that
AEA concentrations are increased in OB, in part at least, due
to a malfunctioning of AEA degradation owing to a missense
polymorphism in fatty acid amide hydrolase. Interestingly, EC
plasma levels have been shown to be diminished post-prandially
or subsequent to oral glucose load and euglycaemic hyperinsuli-
naemic clamp in lean,18 but not in insulin-resistant OB,6,18
suggesting an uncoupling of insulin-induced negative feedback
regulation of ECs derived from the peripheral and adipose
tissues in obese individuals with an insulin-resistant state. The
current study adds further information in that EC plasma levels
also appear to be increased in OB even in a fasting state and,
as it has been also reported more recently,21 in obese type 2 dia-
betes mellitus patients.
Figure 2 Correlation between (A) anandamide, (B)
2-arachidonoylglycerol plasma levels and change of endothelium-
related myocardial blood flow during cold pressor testing in
obesity, respectively.
Figure 3 Correlation between (A) anandamide, (B)
2-arachidonoylglycerol plasma levels and hyperaemic myocardial
blood flows during pharmacological vasodilation with dipyrida-
mole in obesity, respectively.
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Table 5 Univariate analysis in overweight and obesity group
OW OB
DMBF to CPT Hyperaemic MBF DMBF to CPT Hyperaemic MBF
Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value
Age, years 20.18 (20.008 to 0.003) 0.378 20.13 (20.019 to 0.010) 0.525 20.30 (20.007 to 0.001) 0.106 20.49 (20.029 to 0.005) 0.009
BMI, kg/m2 20.035 (20.060 to 0.051) 0.865 0.078 (20.11 to 0.16) 0.704 20.20 (20.010 to 0.003) 0.291 20.066 (20.027 to 0.019) 0.742
Gender, M 20.45 (20.31 to 20.030) 0.010 0.23 (20.17 to 0.61) 0.138 20.28 (20.17 to 20.03) 0.057 20.52 (20.811 to 20.153) 0.006
AEA, ng/mL 20.19 (20.65 to 0.23) 0.337 20.10 (21.42 to 0.84) 0.604 20.37 (20.46 to 20.005) 0.046 20.38 (21.52 to 0.003) 0.051
2-AG, ng/mL 20.17 (20.034 to 0.014) 0.401 20.27 (20.10 to 0.019) 0.174 20.48 (20.017 to 20.003) 0.008 20.45 (20.055 to 20.006) 0.017
SBP, mmHg 20.24 (20.010 to 0.003) 0.231 0.17 (20.009 to 0.024) 0.388 20.28 (20.007 to 0.001) 0.130 20.23 (20.021 to 0.006) 0.246
Total cholesterol, mg/dL 20.032 (20.003 to 0.002) 0.875 0.09 (20.005 to 0.008) 0.643 20.16 (20.002 to 0.001) 0.433 0.013 (20.005 to 0.005) 0.949
LDL cholesterol, mg/dL 20.16 (20.004 to 0.002) 0.436 0.055 (20.006 to 0.008) 0.797 20.22 (20.003 to 0.001) 0.286 20.020 (20.006 to 0.005) 0.926
HDL cholesterol, mg/dL 0.35 (0.0001 to 0.01) 0.076 0.17 (20.008 to 0.020) 0.387 0.25 (20.002 to 0.009) 0.226 0.20 (20.009 to 0.026) 0.324
Triglycerides, mg/dL 20.23 (20.001 to 0.0001) 0.251 20.028 (20.003 to 0.002) 0.891 20.13 (20.001 to 0.001) 0.530 20.118 (20.004 to 0.002) 0.573
Glucose, mg/dL 20.35 (20.013 to 0.001) 0.077 20.068 (20.022 to 0.016) 0.742 0.036 (20.002 to 0.002) 0.857 20.22 (20.010 to 0.003) 0.265
HOMA 20.021 (20.048 to 0.043) 0.925 20.29 (20.15 to 0.029) 0.174 0.13 (20.022 to 0.023) 0.955 0.061 (20.068 to 0.086) 0.811
C-reactive protein, mg/L 0.16 (20.016 to 0.037) 0.435 20.23 (20.10 to 0.028) 0.240 20.015 (20.009 to 0.008) 0.940 0.26 (20.010 to 0.045) 0.204
OW, overweight, OB, Obesity; MBF, myocardial blood flow; CPT, cold pressor testing; BMI, body mass index; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; SBP, systolic blood pressure; LDL cholesterol, low-density lipoprotein
cholesterol; HDL cholesterol, high-density lipoprotein cholesterol; HOMA, homeostasis model assessment for insulin resistance. P-values by analysis of variance.
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As regards PET/CT determined MBF measurements, resting MBFs
in OB were observed to be significantly higher than in CON and
OW, which were related to higher resting heart rates, SBPs and
resulting RPP, indicative of the myocardial workload. The obser-
vation of an increase in myocardial workload in OB associated
with higher resting MBFs is in agreement with a previously
reported activation of the sympathetic nervous system and
renin–angiotensin–aldosterone system and an increase in resting
MBF in OB.22 This may contrast with previous findings,3 where
the resting MBF was not significantly different between CON,
OW, and OB. The reason for this discordant observation
remains uncertain but, most likely, is related to the presence of
a more advanced stage of OB in the current study population
associated with a more enhanced activation of the sympathetic
nervous- and renin–angiotensin–aldosterone system.22 In the
evaluation of coronary circulatory function, however, as observed
in the current and recent investigations,3,4 there was a progressive
decrease in endothelium-dependent MBF responses to CPT from
normal weight CON to OW, and OB. The total vasodilator
capacity was also altered in individuals with increases in body
weight. Thus, alterations of coronary circulatory function were
not only confined to the endothelium but they had already
affected vascular smooth muscle cell function in both groups of
OW and OB.
Concerning the obese study population increases in both AEA
and 2-AG plasma levels were significantly and inversely correlated
with the extent of CPT-induced alterations in MBF and hyperaemic
MBFs, respectively. Such findings may strongly suggest that
increases in EC plasma levels may mediate an abnormal function
of the coronary circulation as a functional precursor of CAD in
OB. Confounding effects related to obesity such as low HDL
cholesterol, insulin resistance, inflammation, various adipocyto-
kines, and/or undetermined factors, however, most likely had
also altered coronary circulatory function. By multivariate analysis,
2-AG plasma levels remained independently associated with
altered hyperaemic MBFs in the current study population with
increasing body weight, whereas no independent association was
observed for the endothelium-related MBF response to CPT.
Thus, altered MBF responses to CPT related to elevated EC
plasma levels appear to contribute to the adverse effects increases
in body weight associated with low HDL cholesterol, insulin
resistance, increases in triglycerides, and micro-inflammation.
Such observations may also suggest differential binding of both
ECs to different parts of the coronary arterial wall. Thus,
someone could speculate that 2-AG may have a higher affinity
and efficacy for CB1- and CB2-receptors of the arteriolar vascular
smooth muscle cells than for the coronary endothelium,6,23 which,
however, needs to be elucidated by experimental investigations.
With regard to possible effects of elevated ECs plasma levels in
OB on coronary circulatory function, the current observations
provide first direct in vivo evidence that increases in AEA and
2-AG may confer adverse effects on both the coronary endo-
thelium and vascular smooth muscle function of the arteriolar
vessel. Support for these in vivo observations comes also from a
more recent experimental investigation in apolipoprotein E-
deficient (ApoE2/2) mice.24 Inhibition of CB1 receptor by rimona-
bant in mice, which were previously shown to exhibit elevated
2-AG levels in the aorta and visceral adipose tissue,9 resulted in
a decrease in aortic reactive oxygen species (ROS) production
and NADPH oxidase activity paralleled by an improvement in
endothelium-dependent vasodilation. These results emphasize
that stimulation of CB1 receptor stimulation by ECs may indeed
stimulate proatherosclerotic mechanisms.24 Endocannabinoids
have also been shown to specifically stimulate CB1 and CB2 on
the vascular endothelium and smooth muscle cells,6 that, as predo-
minantly demonstrated by in vitro studies, may lead to EC stimu-
lated proatherosclerotic effects, such as increases in oxdidative
stress and vascular adhesion molecules like VCAM-1 expression,
monocyte adhesion, and migration into the arterial wall.6,9,24,25
Further investigations, however, are warranted for the identifi-
cation and characterization of the molecular mechanisms by
which ECs affect coronary circulatory function in OB.
Conceptually, an improvement of coronary circulatory function
by preventive medical intervention, for example, with the CB1
antagonist rimonabant, and/or behavioural interventions related
to weight, diet, and physical activity may diminish the association
between obesity and the risk for future cardiovascular events.7,26
A recent study of coronary circulatory function is in support of
this consideration. For example, an improvement of coronary
endothelial function in type 2 diabetes after 1 year follow-up in
response to glucose lowering treatment with metformin and/or
glyburide has been shown more recently to mediate direct preven-
tive effects on the progression of epicardial structural disease.27
These preliminary observations may indeed give rise to the con-
sideration that medical therapy strategies aiming to decrease EC
plasma concentrations in obese individuals, perhaps using new gen-
eration CB1 antagonists with lesser central side effects,6 may
improve coronary circulatory function, thereby leading to an
improvement in cardiovascular prognosis. This hypothesis,
however, necessitates further clinical outcome studies. Finally, it
should be noted that the findings presented were obtained from
a relatively small sample size of patients with predominantly
advanced obesity (median BMI of 41 kg/m2), which may not
necessarily allow definite answers but may stimulate further inves-
tigations in this emerging research field.
Conclusions
This study demonstrates that increased EC plasma levels of AEA
and 2-AG are associated with abnormal coronary circulatory func-
tion in OB. As an impairment of coronary circulatory function may
reflect an early abnormal functional stage of the CAD process,
increases in EC plasma levels may emerge as a novel cardiovascular
risk factor in OB.
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